← All trials
NCT02930161
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2016
- Primary completion
- Aug 1, 2017
- Completion date
- Nov 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 204
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Polysan, Ltd.Lead sponsor
- Military Medical Academy named after SM Kirov, the Russian Ministry of Defense, Hospital Therapeutic Department and ClinicOverall official - principal investigator
- St. Petersburg City Hospital of the Holy Martyr ElizabethOverall official - principal investigator
- State Novosibirsk Regional Clinical HospitalOverall official - principal investigator
- Hepatologist Ltd.Overall official - principal investigator
- Moscow State UniversityOverall official - principal investigator
- BioEqOverall official - principal investigator
- St. Petersburg State Public Medical InstitutionOverall official - principal investigator
- Government of RussiaOverall official - principal investigator
- Russian MilitaryOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.